Corporate News

Alnylam Pharmaceuticals’ subsidiary, Alnylam‑Pharmaceuticals‑Inc (ticker ALNYLAM), disclosed that its investigational therapy for chronic hepatitis delta (CHD) has achieved compelling virologic milestones in late‑stage clinical studies. The company’s combination product—an siRNA agent paired with a monoclonal antibody—was administered monthly by subcutaneous injection and met all primary and key secondary endpoints in the pivotal Phase 3 ECLIPSE 1 trial.

Clinical Efficacy

The Phase 3 ECLIPSE 1 study, presented at the American Association for the Study of Liver Diseases (AASLD) meeting, demonstrated that the majority of participants attained undetectable hepatitis delta virus (HDV) RNA levels and normalization of alanine aminotransferase (ALT) by week 48. These outcomes were consistent across both cirrhotic and non‑cirrhotic subgroups, indicating robust antiviral activity regardless of liver fibrosis stage. Importantly, sustained viral suppression was observed beyond the primary endpoint, suggesting durable treatment effects.

In an expanded Phase 2 SOLSTICE study, all participants who completed 96 weeks of therapy reached undetectable viral levels. A subset who discontinued treatment after 96 weeks maintained a sustained virologic response (SVR) for up to 48 weeks of follow‑up, underscoring the potential for treatment discontinuation without rebound infection. Liver stiffness measurements—an indirect marker of fibrosis—improved or stabilized in most patients, aligning with the virologic response data. The safety profile across both studies remained favorable, with no serious drug‑related adverse events reported.

Mechanistic Insight

The therapeutic platform leverages the precision of small interfering RNA (siRNA) to target HDV RNA transcripts, thereby inhibiting viral protein synthesis at the post‑transcriptional level. Concomitantly, the monoclonal antibody component blocks the interaction between HDV and the hepatitis B virus surface antigen (HBsAg), which is essential for HDV entry and assembly. By simultaneously disrupting viral replication and entry, the combination offers a multi‑layered attack on HDV life cycle, potentially reducing the likelihood of resistance emergence.

Regulatory Trajectory

Alnylam is preparing a comprehensive global regulatory filing for U.S. approval in the second half of 2027. The submission will be supported by data from the ongoing ECLIPSE 2 and ECLIPSE 3 trials, expected to report in early 2027. The company has already secured U.S. Food and Drug Administration (FDA) breakthrough and fast‑track designations, as well as priority status from the European Medicines Agency (EMA), reflecting the unmet medical need in this rare disease. These designations facilitate an accelerated review process and potentially earlier market access.

Market Implications

Chronic hepatitis delta remains an orphan disease with limited approved therapies. Alnylam’s candidate, if approved, could occupy a pivotal position as a disease‑modifying treatment, addressing both viral suppression and liver disease progression. The combination’s subcutaneous route and monthly dosing may improve patient adherence compared with existing regimens that require complex antiviral schedules. However, the ultimate commercial success will hinge on the long‑term durability of response, cost of goods, and the competitive landscape, including emerging HBV/HDV therapies in development by other biotechnology firms.

Conclusion

Alnylam’s recent clinical data reinforce its progress toward delivering a potentially transformative therapy for CHD. The combination of rigorous virologic endpoints, a scientifically sound dual‑mechanism approach, and a favorable safety profile positions the candidate favorably within the regulatory and therapeutic landscape. As additional data from ECLIPSE 2 and ECLIPSE 3 become available, stakeholders will gain clearer insight into the long‑term efficacy, optimal treatment duration, and positioning strategy for this novel therapeutic modality.